Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: luckydog88 who wrote (63106)	5/7/2025 10:06:19 PM
From: ghettogoulash	1 Recommendation Recommended By jhcimmu Respond to of 63285

Thanks for the gumball, Mickey. When SRPT is back to $113-125 in twelve months or less, Micky and Minnie will restore their price targets. Btw, gross margin on revenue is 80%.

To: luckydog88 who wrote (63106)	5/8/2025 9:53:55 AM
From: luckydog88	1 Recommendation Recommended By jhcimmu Respond to of 63285

couple of more analysts on SPRT today/yesterday afternoon: Wells Fargo analyst Yanan Zhu maintains Sarepta Therapeutics(SRPT) with a Overweight and lowers the price target from $115 to $100. UBS Cuts Price Target on Sarepta Therapeutics to $85 From $188, Keeps Buy Rating RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics(SRPT) with a Sector Perform and lowers the price target from $87 to $58.